Article

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

2024-04-20

Abstract excerpt

This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICI). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy. We conducted an analysis of single-cell transcriptomes from 33 lung cancer biopsy samp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 68d41ddc-54ff-572a-851e-962ccde2ff66
DOI: 10.1101/2024.04.15.589544

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerDOI 10.1101/2024.04.15.589544Read

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity Read

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read

Comprehensive characterization of early-stage Non-Small Cell Lung cancers with multi-modal data integrationSemantic proximity Read

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.Semantic proximity Read

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerSemantic proximity Read

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity Read

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity Read

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read

Identification and validation of an inflammatory response-related signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancerSemantic proximity Read

An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.Semantic proximity Read

Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance.Semantic proximity Read